Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics reported interim revenues of £36.3 million for the six months to 31 December 2025, up 7% despite phasing out unregistered products in Germany, but swung to an operating loss before R&D of £2.5 million as it increased investment in launches and late‑stage trials. The balance sheet was reshaped by the repayment of shareholder loans via warrant exercises and a reduction in total debt, while a new £40 million senior secured facility from Hayfin post‑period bolsters liquidity for growth projects.
Operationally, the group secured German marketing authorisation for its subcutaneous grass pollen immunotherapy Grassmuno and launched it in January 2026 to strong early clinician uptake, positioning it as a key growth driver in its core German market. Clinical programmes advanced with a paediatric Phase III trial of Grass MATA MPL progressing as planned and the VLP Peanut short‑course vaccine meeting its Phase I/IIa primary safety endpoint with robust immunomodulatory data, while the company also began exploring a potential dual primary listing in Hong Kong to support its international ambitions.
The most recent analyst rating on (GB:AGY) stock is a Sell with a £11.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on AGY Stock
According to Spark, TipRanks’ AI Analyst, AGY is a Neutral.
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology group specialising in allergy immunotherapies. Its portfolio includes registered subcutaneous treatments for seasonal and perennial allergies, with Germany as its largest market and strategic plans to expand key products into wider European, non‑EU and U.S. markets.
Average Trading Volume: 273,644
Technical Sentiment Signal: Buy
Current Market Cap: £658.6M
For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.